Literature-based review examines non-opioid therapies for pain management in sickle cell disease, suggesting new strategies.
Pain is a debilitating complication of sickle cell disease (SCD), driven by recurrent vaso-occlusive crises and chronic pain syndromes involving central sensitization and neuropathic mechanisms. Although opioid medications remain first-line therapy for acute pain, there are limitations that highlight the need for effective adjunctive approaches. Available data support non-opioid pharmacologic therapies including acetaminophen and nonsteroidal anti-inflammatory drugs as components of multimodal analgesia, with emerging evidence for therapies targeting neuropathic and centralized pain. Non-pharmacologic interventions such as cognitive behavioral therapy have also demonstrated potential benefits as adjunctive strategies in SCD pain management. This literature review examines evidence supporting non-opioid pharmacologic and non-pharmacologic therapies for pain management in SCD and is based on structured searches of PubMed, MEDLINE, and Cochrane databases.
No takes yet. Share an insight, caveat, or question.
Riley et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: